Brittany Bordonaro, PA
Medical · Hartford, CTNPI 1548630999
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 258 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,482, more than ten times the $216 reported in 2022. Among medical clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$525
- Ardelyx, Inc.$482
- Takeda Pharmaceuticals U.S.A., Inc.$395
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$359
- Madrigal Pharmaceuticals$341
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,38997%
- Education$1393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,264 |
| Johnson & Johnson(2 entities) | 24 | $525 |
| Ardelyx, Inc. | 21 | $482 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $395 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $359 |
| Madrigal Pharmaceuticals | 7 | $341 |
| Regeneron Healthcare Solutions, Inc. | 10 | $233 |
| Pfizer | 18 | $203 |
| QOL Medical, LLC | 5 | $193 |
| Exact Sciences | 8 | $163 |
| Phathom Pharmaceuticals, Inc. | 8 | $163 |
| Bristol Myers Squibb | 7 | $162 |
| Boston Scientific | 1 | $140 |
| Lilly USA, LLC | 6 | $126 |
| Daiichi Sankyo Inc. | 1 | $102 |
| Aimmune Therapeutics, Inc. | 1 | $92 |
| Sandoz | 5 | $91 |
| Intercept Pharmaceuticals, Inc. | 4 | $84 |
| Boehringer Ingelheim | 4 | $72 |
| Ironwood Pharmaceuticals, Inc | 3 | $64 |
| Gilead | 3 | $60 |
| Celltrion USA Inc. | 2 | $53 |
| Ferring Pharmaceuticals Inc. | 3 | $50 |
| Amgen | 2 | $42 |
| Novo Nordisk | 1 | $22 |
| GSK | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBSRELA$230
- EXALT Model D$140
- REZDIFFRA$123
- Rinvoq$114
- Enhertu$102
How this compares
$5,528 in reported general payments places this provider in the 90th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 18 | $52,248 |
| LinzessLinaclotide | 75 | $51,281 |
| XifaxanRifaximin | 20 | $48,686 |
| TrulancePlecanatide | 13 | $10,584 |
| MotegrityPrucalopride Succinate | 12 | $9,541 |
| Dexlansoprazole DrDexlansoprazole | 26 | $7,274 |
| Mesalamine | 26 | $4,667 |
| Pantoprazole Sodium | 266 | $3,963 |
| Omeprazole | 247 | $3,182 |
| Budesonide EcBudesonide | 14 | $2,965 |
| Sucralfate | 16 | $2,008 |
| Colestipol Hcl | 46 | $1,661 |
| Balsalazide Disodium | 11 | $1,367 |
| Famotidine | 66 | $1,051 |
| Esomeprazole Magnesium | 28 | $864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,264 | $103,52993 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $359 | $59,27033 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $395 | $9,54112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 592 medical providers in Connecticut.
Other medical in Hartford
- Pamela CondonHartford$16K
- Erin FrankHartford$15K
- Stephanie HullHartford$10K
- Kaitland ArdHartford$9K
- Jeremy BakerHartford$8K
- Leah PawelczykHartford$6K
- Kelsey BurgerHartford$6K
- Arianna YouellHartford$5K
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.